公开(公告)号：US20190290727A1

公开(公告)日：2019-09-26

申请号：US16419818

申请日：2019-05-22

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Jens FRITSCHE ,  Toni WEINSCHENK ,  Steffen WALTER ,  Peter LEWANDROWSKI ,  Harpreet SINGH

IPC: A61K38/17 ,  C07K7/06 ,  A61K39/00 ,  A61P35/00 ,  G01N33/50

Abstract: A method of treating a patient who has gastric cancer, gastrointestinal cancer, colorectal cancer, pancreatic cancer, lung cancer, and/or renal cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has gastric cancer, gastrointestinal cancer, colorectal cancer, pancreatic cancer, lung cancer, and/or renal cancer. A method of treating a patient who has cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the cancer.

公开(公告)号：US20180125929A1

公开(公告)日：2018-05-10

申请号：US15639506

申请日：2017-06-30

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Jens FRITSCHE ,  Toni WEINSCHENK ,  Steffen WALTER ,  Peter LEWANDROWSKI ,  Harpreet SINGH

IPC: A61K38/17 ,  G01N33/50 ,  C07K7/06 ,  A61K39/00

CPC classification number: A61K38/1709 ,  A61K39/0011 ,  A61K2039/5158 ,  A61K2039/572 ,  A61K2039/585 ,  A61P35/00 ,  C07K7/06 ,  C07K2319/00 ,  G01N33/505

Abstract: A method of treating a patient who has gastric cancer, gastrointestinal cancer, colorectal cancer, pancreatic cancer, lung cancer, and/or renal cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has gastric cancer, gastrointestinal cancer, colorectal cancer, pancreatic cancer, lung cancer, and/or renal cancer. A method of treating a patient who has cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the cancer.

公开(公告)号：US20180000896A1

公开(公告)日：2018-01-04

申请号：US15639310

申请日：2017-06-30

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Jens FRITSCHE ,  Toni WEINSCHENK ,  Steffen WALTER ,  Peter LEWANDROWSKI ,  Harpreet SINGH

IPC: A61K38/17 ,  C07K7/06 ,  A61K39/00 ,  G01N33/50

CPC classification number: A61K38/1709 ,  A61K39/0011 ,  A61K2039/5158 ,  A61K2039/572 ,  A61K2039/585 ,  A61P35/00 ,  C07K7/06 ,  C07K2319/00 ,  G01N33/505

Abstract: A method of treating a patient who has gastric cancer, gastrointestinal cancer, colorectal cancer, pancreatic cancer, lung cancer, and/or renal cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has gastric cancer, gastrointestinal cancer, colorectal cancer, pancreatic cancer, lung cancer, and/or renal cancer. A method of treating a patient who has cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the cancer.